130 results on '"Welén, Karin"'
Search Results
2. Osteoclasts directly influence castration-resistant prostate cancer cells
3. Magnetic Resonance Imaging as a Tool for Monitoring Intratibial Growth of Experimental Prostate Cancer Metastases in Mice
4. Acoustic enrichment of heterogenous circulating tumor cells and clusters from patients with metastatic prostate cancer
5. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
6. Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer
7. Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
8. Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression
9. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
10. Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.013. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
11. Prostate diseases – role of sex steroids and their inhibitors
12. Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C
13. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment
14. The roles of RUNX2 and osteoclasts in regulating expression of steroidogenic enzymes in castration-resistant prostate cancer cells
15. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model
16. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer
17. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
18. Inhibition of Metastasis in a Castration Resistant Prostate Cancer Model by the Quinoline-3-Carboxamide Tasquinimod (Abr-215050)
19. Castration Resistant Prostate Cancer Is Associated with Increased Blood Vessel Stabilization and Elevated Levels of Vegf and Ang-2
20. RGS2 is prognostic for development of castration resistance and cancer‐specific survival in castration‐resistant prostate cancer
21. Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells
22. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer
23. The Prostatic Environment Suppresses Growth of Androgen-Independent Prostate Cancer Xenografts: An Effect Influenced by Testosterone
24. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models
25. Prostate Cancer Progression into Androgen Independency Is Associated With Alterations in Cell Adhesion and Invasivity
26. Transition of an Androgen-Dependent Human Prostate Cancer Cell Line Into an Androgen-Independent Subline Is Associated With Increased Angiogenesis
27. Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients
28. Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
29. AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer
30. ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors
31. Abstract B071: Circulating tumor cells as liquid biopsies of skeletal metastases from prostate cancer
32. Abstract B082: Osteolytic and osteoblastic prostate cancer cells remotely trigger different responses in the bone marrow niche
33. Circulating tumor cells mirror bone metastatic phenotype in prostate cancer
34. Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer
35. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer
36. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis
37. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment
38. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies
39. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer
40. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)
41. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang‐2
42. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model
43. ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors
44. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer
45. Altered expression of genes regulating angiogenesis in experimental androgen‐independent prostate cancer
46. Transition of an androgen‐dependent human prostate cancer cell line into an androgen‐independent subline is associated with increased angiogenesis
47. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.
48. ADAMTS1 alters blood vessel morphology andTSP1 levels in LNCaP and LNCaP-19 prostatetumors.
49. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer.
50. Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.